GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

At the highly anticipated GLP-1-Based Therapeutics Summit, you and your peers will experience 8+ hours of exceptional networking, while navigating the surge in evidence for GLP-1 applications ...

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

Diabetes may play a role in your weight, including weight loss, when you have type 1 or type 2 diabetes. This can be a symptom of unmanaged or undiagnosed diabetes, but it can also be due to other ...

Strategic initiatives include partnerships for GLP-1 drugs and distribution agreements for new products ... So again, I think despite the fact that our safety products and our pin needles had ...